Previous 10 | Next 10 |
2023-07-28 12:49:57 ET Gainers: Unique Fabricating ( UFAB ) +74% . Reata Pharmaceuticals ( RETA ) +52% . INVO Bioscience ( INVO ) +45% . Bluejay Diagnostics ( BJDX ) +44% . View ( VIEW ) +40% . iClick Interactive Asia Group L...
2023-07-28 10:11:25 ET Gainers: Reata Pharmaceuticals ( RETA ) +53% . Bluejay Diagnostics ( BJDX ) +48% . INVO Bioscience ( INVO ) +26% . OKYO Pharma ( OKYO ) +24% . BIOLASE ( BIOL ) +10% . Losers: Tonix Pharmaceutica...
2023-07-28 07:18:20 ET Biogen Inc. ( NASDAQ: BIIB ) agreed to buy Reata Pharmaceuticals ( NASDAQ: RETA ) for $172.50 per share in cash, or an enterprise value of about $7.3 billion. Reata shares were halted for news pending. Biogen fell 3.6% in premarket tradin...
SKYCLARYS ® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth, adding a highly complementary innovative product in an area...
2023-07-27 09:50:41 ET Reata Pharmaceuticals ( NASDAQ: RETA ) ticked up 2% amid some takeover speculation. There's some speculation that Reata Pharma ( RETA ) has attracted takeover interest, according to a Betaville "uncooked" alert, which cited people following the m...
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.04% on the day to $110.26. Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patient...
2023-07-06 12:51:46 ET TD Cowen initiated coverage of Reata Pharmaceuticals ( NASDAQ: RETA ) with an outperform rating, citing the revenue potential of the company's recently approved drug Skyclarys for the treatment of the ultra-rare disease Friedrich's ataxia, or FA. The inves...
2023-06-28 07:56:35 ET Reata Pharmaceuticals ( NASDAQ: RETA ) added ~8% pre-market Wednesday after announcing that the FDA approved a prior approval supplement (PAS) related to its Friedreich’s ataxia therapy, Skyclarys, which the regulator greenlighted in March. The ...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, annou...
2023-06-23 11:12:16 ET As Wall Street approaches the midpoint of 2023, many mid-cap stocks have provided investors with sizable returns. Of the roughly 1,000 mid-cap stocks available for investors, 101 of them have returned 50% or more since the end of 2022. This includes several ralli...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...